DULERA
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $140,160 | 6 | 3 |
| 2019 | $3,227 | 24 | 22 |
| 2018 | $162,235 | 89 | 21 |
| 2017 | $1.0M | 482 | 66 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.3M | 474 | 96.8% |
| Consulting Fee | $38,580 | 12 | 2.9% |
| Travel and Lodging | $3,077 | 9 | 0.2% |
| Food and Beverage | $1,510 | 106 | 0.1% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A phase III, randomized, active-controlled, parallel-group clinical trial to study the efficacy and long-term safety of mometasone furoate , formoterol fumarate MF,F, compared with mometasone furoate MF, in children with persistent asthma. | Merck Sharp & Dohme Corporation | $567,956 | 0 |
| A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone Furoate,Formoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Adolescents and Adults With Persistent Asthma Protocol No. P06241 also known as P202 | Merck Sharp & Dohme Corporation | $519,492 | 4 |
| Effect of IL-4R?R576 polymorphism on response to Dupilumab in Asthma, a Genotype stratified, randomized-placebo controlled trial | Organon LLC | $140,108 | 0 |
| Improving Adherence in the Real World Dulera Evidence-Based Adherence Monitoring Pilot Study | Merck Sharp & Dohme Corporation | $60,125 | 0 |
Top Doctors Receiving Payments for DULERA — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | General Practice | Saratoga, CA | $17.23 | 1 |
| , MD | Family Medicine | Los Gatos, CA | $17.23 | 1 |
| , MD | Internal Medicine | Muskegon, MI | $17.11 | 1 |
| , D.O | Internal Medicine | Muskegon, MI | $17.11 | 1 |
| , D.O | Internal Medicine | Muskegon, MI | $17.11 | 1 |
| , D.O | Internal Medicine | Muskegon, MI | $17.11 | 1 |
| , M.D | Family Medicine | The Villages, FL | $16.65 | 1 |
| , D.O | Pulmonary Disease | Erie, PA | $16.58 | 1 |
| , MD | Internal Medicine | Staten Island, NY | $16.45 | 1 |
| , M.D | Hospitalist | Thibodaux, LA | $16.44 | 1 |
| , M.D | Student in an Organized Health Care Education/Training Program | New Orleans, LA | $16.44 | 1 |
| , MD | Allergy & Immunology | Albany, GA | $16.16 | 1 |
| , MD | Family Medicine | Monroe, LA | $14.64 | 1 |
| , MD | Specialist | North Bergen, NJ | $14.57 | 1 |
| , MD | Pulmonary Disease | North Bergen, NJ | $14.57 | 1 |
| , M.D | Allergy | Newark, DE | $14.30 | 1 |
| , MD | Internal Medicine | Florence, SC | $14.27 | 1 |
| , M.D | Pediatric Pulmonology | Huntsville, AL | $14.19 | 1 |
| , M.D | Pediatric Pulmonology | Huntsville, AL | $14.19 | 1 |
| , M.D | Internal Medicine | Redwood City, CA | $14.13 | 1 |
| , M.D | Family Medicine | Ridgewood, NY | $13.81 | 1 |
| , M.D | Internal Medicine | Ridgewood, NY | $13.81 | 1 |
| , M.D | Pulmonary Disease | Bowling Green, KY | $13.52 | 1 |
| Randall Lanier | — | Bowling Green, KY | $13.52 | 1 |
| , MD | Internal Medicine | Springfield Gardens, NY | $13.43 | 1 |
Manufacturing Companies
- Merck Sharp & Dohme Corporation $1.2M
- Organon LLC $140,108
Product Information
- Type Drug
- Total Payments $1.3M
- Total Doctors 110
- Transactions 601
About DULERA
DULERA is a drug associated with $1.3M in payments to 110 healthcare providers, recorded across 601 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2021. In 2021, $140,160 was paid across 6 transactions to 3 doctors.
The most common payment nature for DULERA is "Unspecified" ($1.3M, 96.8% of total).
DULERA is associated with 4 research studies, including "A phase III, randomized, active-controlled, parallel-group clinical trial to study the efficacy and long-term safety of mometasone furoate , formoterol fumarate MF,F, compared with mometasone furoate MF, in children with persistent asthma." ($567,956).